A new experimental therapy designed to support muscle regeneration has shown encouraging results in a mouse model of facioscapulohumeral muscular dystrophy (FSHD), offering fresh hope for future treatment approaches for the condition.

The therapy, known as SAT-3247, is being developed by Satellos Bioscience and is currently being explored primarily for Duchenne muscular dystrophy (DMD). Researchers have now reported that the treatment also improved muscle function in mice engineered to model FSHD.

Unlike many experimental FSHD therapies that aim to directly suppress the toxic DUX4 protein, SAT-3247 works differently. The drug targets a protein called AAK1, which plays a role in muscle stem cell regeneration and repair. Scientists believe enhancing this regenerative pathway could help muscles recover more effectively from ongoing damage.

In the preclinical study, mice treated with SAT-3247 demonstrated significant improvements in muscle strength over a 12-week period. Researchers observed benefits in both male and female mice, with the strongest improvements seen at certain dosing levels.

FSHD is one of the most common muscular dystrophies, affecting the muscles of the face, shoulders, upper arms and, over time, other parts of the body. Currently, there are no approved disease-modifying treatments specifically for FSHD.

Researchers involved in the work say the findings are particularly important because SAT-3247 may help restore muscle regeneration independently of the underlying genetic cause of the disease. This means the approach could potentially benefit both FSHD1 and FSHD2 patients.

The work was supported in part by the FSHD Canada Foundation, with Satellos stating that the results strengthen the case for expanding development of the therapy into FSHD clinical programmes.

While these results are still early-stage and limited to animal studies, they represent another encouraging step forward in the growing global effort to develop effective treatments for FSHD. Further clinical studies will be needed to determine whether the therapy can safely provide similar benefits in people living with the condition.